胡晓春 - 上海大学

个人简介

胡晓春，副教授，2019年9月毕业于同济大学，获博士学位（导师：石硕教授）。2020年1月至2022年12月在同济大学附属东方医院从事博士后研究工作（合作导师：董春燕主任医师），2022年12月进入上海大学医学院工作。主要从事化疗药物前药的设计合成、生物相容性抗肿瘤纳米材料的构建及其在肿瘤治疗方面的应用研究，以第一作者或共同第一作者在J. Control. Release, Small, Adv. Healthc. Mater., J. Nanobiotechnol., Chem. Commun., ACS Appl. Mater. Inter., Acta Biomater., J. Mater. Chem. B, Chem-Eur. J., Inorg. Chem. Front.和Dalton Trans.等国内外权威期刊上发表十余篇SCI论文。入选上海市2020年度超级博士后，主持国家自然科学基金青年基金、中国博士后科学基金面上项目（二等）。

研究领域

1. 化疗药物前药的设计合成； 2. 生物相容性抗肿瘤纳米材料的构建及其在肿瘤治疗方面的应用研究

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

[1] X. Hu#, H. Li#, R. Li, S. Qiang, M. Chen, S. Shi*, C. Dong*, A Phase-Change Mediated Intelligent Nanoplatform for Chemo/Photothermal/Photodynamic Therapy of Cancer, Adv Healthc Mater (2022) 2202245.（IF=11.092） [2] X. Hu#, R. Li#, W. Wu, K. Fang, Z. Zhu, Y. Wang, L. Zhou, M. Chen, C. Dong*, S. Shi*, A Fe(III)-porphyrin-oxaliplatin(IV) nanoplatform for enhanced ferroptosis and combined therapy, J. Control. Release. 348 (2022) 660-671.（IF=11.467） [3] R. Li#, X. Hu#, F. Shang, W. Wu, H. Zhang, Y. Wang, J. Pan, S. Shi*, C. Dong*, Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals, Acta Biomater. 148 (2022) 218-229.（IF=10.633） [4] S. Qiang#, X. Hu#, R. Li, W. Wu, K. Fang, H. Li, Y. Sun, S. Liang, W. Zhao, M. Wang, Y. Lin, S. Shi*, C. Dong*, CuS Nanoparticles-Loaded and Cisplatin Prodrug Conjugated Fe(III)-MOFs for MRI-Guided Combination of Chemotherapy and NIR-II Photothermal Therapy, ACS Appl. Mater. Inter. 14(32) (2022) 36503-36514.（IF=10.383） [5] J. Liu#, X. Hu#, L. Feng, Y. Lin, S. Liang, Z. Zhu, S. Shi*, C. Dong*, Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K/mTOR inhibitor and resists HIF-1α-dependent tumor hypoxia adaptation, J Nanobiotechnology 20(1) (2022) 187.（IF=9.429） [6] W. Zhao#, X. Hu#, W. Li, R. Li, J. Chen, L. Zhou, S. Qiang, W. Wu, S. Shi*, C. Dong*, M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy, Small 17(13) (2021) 2007051.（IF=15.153） [7] X. Hu#, Y. Lu#, W. Zhao, M. Sun, R. Li, L. Feng, T. Yao, C. Dong*, S. Shi*, A PDA-DTC/Cu-MnO2 Nanoplatform for MR Imaging and Multi-Therapy for Triple-Negative Breast Cancer Treatment, Chem. Commun. 57(34) (2021) 4158-4161.（IF=6.065） [8] X. Hu#, Y. Lu#, L. Zhou, L. Chen, T. Yao, S. Liang, J. Han, C. Dong*, S. Shi*, Post-Synthesis Strategy to Integrate Porphyrinic Metal-Organic Frameworks with CuS NPs for Synergistic Enhanced Photo-Therapy, J. Mater. Chem. B 8(5) (2020) 935-944.（IF=7.571） [9] X. Hu, Y. Lu, C. Dong, W. Zhao, X. Wu, L. Zhou, L. Chen, T. Yao*, S. Shi*, A RuII Polypyridyl Alkyne Complex Based Metal-Organic Frameworks for Combined Photodynamic/Photothermal/Chemotherapy, Chem. Eur. J 26(7) (2020) 1668-1675.（IF=5.0） [10] X. Hu#, Z. Xu#, J. Hu, C. Dong, Y. Lu, X. Wu, M. Wumaier, T. Yao*, S. Shi*, A redox-activated theranostic nanoplatform: toward glutathione-response imaging guided enhanced-photodynamic therapy, Inorg. Chem. Front. 6(10) (2019) 2865-2872.（IF=7.8） [11] X. Hu#, Y. Lu#, X. Shi, T. Yao, C. Dong*, S. Shi*, Integrating in Situ Formation of Nanozymes with Mesoporous Polydopamine for Combined Chemo, Photothermal and Hypoxia-Overcoming Photodynamic Therapy, Chem. Commun. 55(98) (2019) 14785-14788. （IF=6.065） [12] X. Hu, D. Yang, T. Yao*, R. Gao, M. Wumaier, S. Shi*, Regulation of multi-factors (tail/loop/link/ions) for G-quadruplex enantioselectivity of Δ- and Λ- [Ru(bpy)2(dppz-idzo)]2+, Dalton Trans. 47(15) (2018) 5422-5430. （IF=4.6）